Combinatorial immunotherapy may improve the efficacy of neoadjuvant checkpoint inhibitors in locoregionally advanced melanoma. In this issue of Cancer Cell, Davar and colleagues report a promising phase 2 neoadjuvant trial of the TLR9 agonist vidutolimod in combination with nivolumab. Analyses suggest a unique myeloid expression signature is associated with response.
Cedric Pobel, MD, Gustave Roussy, Villejuif, France, discusses the identification of prognostic biomarkers for radiographic progression-free survival (rPFS) and overall survival (OS) in the PEACE-1…
Researchers compared an investigational hand therapy intervention with traditional occupational therapy to prevent CIPN due to chemotherapy for pancreatic cancer.
On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.
To celebrate Native American Heritage Month, we spoke with Karina Walters, Ph.D., M.S.W., Director of the NIH Tribal Research Health Office (THRO). Dr. Walters, an…
Read interviews with seven early career researchers, published in ASHG journals American Journal of Human Genetics and HGG Advances, who describe their career journeys, roadblocks,…
Explore the program for the AACR Special Conference in Cancer Research: Translating Targeted Therapies in Combination with Radiotherapy.
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Fully 1,600 cancer treatments and vaccines are in development, according to speakers at an AMCP Nexus 2024 presentation, in Las Vegas.
In this issue of Blood, Hu and colleagues show that reduced Yes-associated protein 1 (YAP1) expression in megakaryocytes (MK), via an impaired interaction
Key PointsOutcomes with single-agent gilteritinib across 38 National Health Service hospitals mirror those seen in clinical trials.Patients with adverse ka
